SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD

(2017) Markus P. Schneider et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

(2016) Nikolaus Marx et al.   EUROPEAN HEART JOURNAL

Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes

(2016) Brian Tomlinson et al.   Expert Opinion on Drug Metabolism & Toxicology

Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive MedicationNovelty and Significance

(2016) Giuseppe Mancia et al.   HYPERTENSION

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study

(2016) Markus Scheerer et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?

(2015) J. A. Lovshin et al.   CURRENT HYPERTENSION REPORTS

Agreement Between 24-Hour Salt Ingestion and Sodium Excretion in a Controlled EnvironmentNovelty and Significance

(2015) Kathrin Lerchl et al.   HYPERTENSION

Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease

(2015) Konstantinos P. Imprialos et al.   JOURNAL OF HYPERTENSION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

23Na Magnetic Resonance Imaging of the Lower Leg of Acute Heart Failure Patients during Diuretic Treatment

(2015) Matthias Hammon et al.   PLoS One

Salt intake assessed by 24 h urinary sodium excretion in a random and opportunistic sample in Australia

(2014) Mary-Anne Land et al.   BMJ Open

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

(2013) Mei Zhang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

23 Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients

(2013) Christoph Kopp et al.   HYPERTENSION

Biomedical applications of sodium MRI in vivo

(2013) Guillaume Madelin et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Salt and Hypertension: Is Salt Dietary Reduction Worth the Effort?

(2012) Tiberio M. Frisoli et al.   AMERICAN JOURNAL OF MEDICINE

23 Na Magnetic Resonance Imaging of Tissue Sodium

(2011) Christoph Kopp et al.   HYPERTENSION

Mononuclear Phagocyte System Depletion Blocks Interstitial Tonicity-Responsive Enhancer Binding Protein/Vascular Endothelial Growth Factor C Expression and Induces Salt-Sensitive Hypertension in Rats

(2010) Agnes Machnik et al.   HYPERTENSION

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C–dependent buffering mechanism

(2009) Agnes Machnik et al.   NATURE MEDICINE